Stockscreener 앱 받기
49.91
0.54%
0.27
시간 외 거래:
49.87
-0.04
-0.08%
Moderna Inc 주식(MRNA)의 최신 뉴스
Moderna Inc. Stock (US60770K1034): valuation focus as biotech name trades in S&P 500 mid-range - AD HOC NEWS
Asset turnover of Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs – BCBA:MRNA.CI - TradingView
Moderna, Inc. Shs Cert Deposito Arg Repr 0.0526315789 Shs Revenue Breakdown – BCBA:MRNA.CI - TradingView
Moderna (MRNA) Stock Looks Slightly Overvalued After Recent Rebound In Mixed Return Picture - Yahoo Finance
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock? - The Motley Fool
Moderna Gains Almost 8% With Nasdaq Recovery; Cancer Vaccine Pipeline Still a Key Focus - TechStock²
Moderna Says New COVID Vax Doesn't Infringe BioNTech IP - Law360
WINTON GROUP Ltd Invests $800,000 in Moderna, Inc. $MRNA - MarketBeat
Nicollet Investment Management Inc. Acquires Shares of 30,413 Moderna, Inc. $MRNA - MarketBeat
Moderna's Case for Vaccinating Children: Strong Data, Stronger Questions - trialsitenews.com
Moderna, Inc. $MRNA Shares Sold by Letko Brosseau & Associates Inc. - MarketBeat
Moderna Inc stock (US60770K1079): Legal chief share sale and vaccine pipeline keep volatility high - AD HOC NEWS
Moderna Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Moderna’s mRNA-4194 cleared for clinic for Lynch syndrome - BioWorld News
Moderna Inc. stock (US60770K1034): Bank of America lifts price target after strong run - AD HOC NEWS
Does Moderna Need to Start Making Money? - The Globe and Mail
Newlands Management Operations LLC's Moderna Inc(MRNA) Holding History - GuruFocus
Capital World Investors Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome - Investing News Network
AIPLA, NAM Rally Behind Moderna's Fight Over Vax Patents - Law360
Moderna’s Lynch syndrome cancer vaccine trial gets UK approval - Investing.com UK
Moderna’s Lynch syndrome cancer vaccine trial gets UK approval By Investing.com - Investing.com South Africa
Inherited cancer risk for 1 in 300: Moderna mRNA trial targets Lynch syndrome - Stock Titan
Moderna CLO Klinger sells $173,550 in shares By Investing.com - Investing.com India
Moderna CLO Klinger sells $173,550 in shares - Investing.com
Moderna (MRNA) legal chief sells 3,471 shares, exercises options and RSUs - Stock Titan
Moderna (MRNA) CFO details RSU vesting and tax share withholding in Form 4 - Stock Titan
MRNA Maintained by B of A Securities -- Price Target Raised to $34 - GuruFocus
Moderna (NASDAQ:MRNA) Price Target Raised to $34.00 - MarketBeat
Moderna, Inc. (MRNA) Stock Analysis: Evaluating The Potential Amidst Volatility - DirectorsTalk Interviews
Havemeyer Place LP Takes Position in Moderna, Inc. $MRNA - MarketBeat
CIBC Asset Management Inc Increases Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Aufman Associates Inc Has $1.27 Million Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
How Investors May Respond To Moderna (MRNA) mRNA Advances in Personalized Cancer and Emerging Infectious Diseases - Yahoo Finance
Norges Bank Makes New Investment in Moderna, Inc. $MRNA - MarketBeat
MRNA Stock Quote Price and Forecast - CNN
Moderna | History, Innovation, Challenges, & Facts | Britannica Money - Britannica
Why Is Moderna (MRNA) Stock Rocketing Higher Today - Yahoo Finance
Moderna gets good news as it searches for life after Covid - Yahoo Finance Singapore
[144] Moderna, Inc. SEC Filing - Stock Titan
Moderna Inc (MRNA) Stock Price, Trades & News - GuruFocus
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
Moderna Stock: Is MRNA Outperforming the Health Care Sector? - Yahoo Finance
Moderna Inc. stock (US60770K1034): EMA committee backs new RSV vaccine as shares bounce on Nasdaq - AD HOC NEWS
Moderna (MRNA) Climbs 7.5% Ahead of Next Week’s Key Updates - Insider Monkey
Moderna rallies on renewed optimism around its Merck-partnered melanoma vaccine program - Quiver Quantitative
Moderna (MRNA) CFO exercises 2,475 RSUs, 1,197 shares withheld for taxes - Stock Titan
Moderna (MRNA) CLO converts RSUs into stock while 1,047 shares withheld for taxes - Stock Titan
Moderna (MRNA) president exercises RSUs, reports tax share withholding - Stock Titan
Moderna (NASDAQ:MRNA) Trading 8.1% HigherShould You Buy? - MarketBeat
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion - Investing News Network
HEALTH ROUNDS-Radiation-emitting implant improves outcomes after brain cancer surgery - marketscreener.com
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026 - Yahoo Finance
Moderna Launches Moderna Direct with “eCommerce Powered by FFF Enterprises™” - Yahoo Finance
Moderna CEPI Ebola Vaccine Work Highlights Broader Infectious Disease Ambitions - Yahoo Finance
Moderna to Present at Upcoming Conference in June 2026 - Investing News Network
MRNA Partners With CEPI to Develop Vaccine for Bundibugyo Ebolavirus - Zacks Investment Research
UBS Lifts Valuation On Moderna, Inc. (MRNA) Ahead of Key Pipeline Catalysts - Insider Monkey
Biotech Movers: Moderna, Iovance, ALHC, SMMT in Focus - Gotrade
ASCO: Moderna’s mRNA-based melanoma vaccine shows ‘encouraging’ 5-year survival - BioSpace
Moderna, Inc. $MRNA Shares Acquired by Lingotto Investment Management LLP - MarketBeat
Moderna and other groups get $60mln to develop Ebola vaccine - ZAWYA
1.04%
0.76%
자본화:
|
볼륨(24시간):